Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the ...
Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the ...
ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous ...
Aphaia’s lead formulation orchestrates a comprehensive hormonal response from nutrient-sensing cells with potential to modify the course of obesity and associated metabolic diseases. It is currently ...
ZUG, Switzerland and SAN JUAN, Puerto Rico, April 25, 2023 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine ...
ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous ...
Second Phase 2 trial builds on encouraging initial results from a prior Phase 2 study Aphaia’s formulation activates gastrointestinal nutrient-sensing signaling pathways to modify the course of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results